imatinib amomed õhukese polümeerikattega tablett
amomed pharma gmbh - imatiniib - õhukese polümeerikattega tablett - 400mg 60tk; 400mg 180tk; 400mg 90tk; 400mg 120tk; 400mg 30tk
azithromycin teva dispergeeruv tablett
teva pharma b.v. - asitromütsiin - dispergeeruv tablett - 500mg 12tk; 500mg 6tk; 500mg 24tk; 500mg 3tk; 500mg 2tk; 500mg 1tk
imatinib sandoz õhukese polümeerikattega tablett
sandoz pharmaceuticals d.d. - imatiniib - õhukese polümeerikattega tablett - 400mg 80tk; 400mg 50tk; 400mg 60tk; 400mg 30tk
varlota õhukese polümeerikattega tablett
alvogen pharma trading europe eood - erlotiniib - õhukese polümeerikattega tablett - 150mg 30tk
imatinib amomed õhukese polümeerikattega tablett
amomed pharma gmbh - imatiniib - õhukese polümeerikattega tablett - 100mg 180tk; 100mg 120tk; 100mg 60tk
azithromycin teva dispergeeruv tablett
teva pharma b.v. - asitromütsiin - dispergeeruv tablett - 250mg 12tk; 250mg 1tk; 250mg 3tk; 250mg 24tk; 250mg 2tk
varlota õhukese polümeerikattega tablett
alvogen pharma trading europe eood - erlotiniib - õhukese polümeerikattega tablett - 50mg 30tk
salofalk gastroresistentne tablett
dr. falk pharma gmbh - mesalasiin - gastroresistentne tablett - 500mg 50tk
xtandi
astellas pharma europe b.v. - ensalutamiid - eesnäärmevähk - endokriinset ravi - xtandi is indicated for:the treatment of adult men with metastatic hormone-sensitive prostate cancer (mhspc) in combination with androgen deprivation therapy (see section 5. the treatment of adult men with high-risk non-metastatic castration-resistant prostate cancer (crpc) (see section 5. the treatment of adult men with metastatic crpc who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy in whom chemotherapy is not yet clinically indicated (see section 5. the treatment of adult men with metastatic crpc whose disease has progressed on or after docetaxel therapy.
erlotinib sandoz õhukese polümeerikattega tablett
sandoz pharmaceuticals d.d. - erlotiniib - õhukese polümeerikattega tablett - 150mg 30tk